Syndax Pharmaceuticals SNDX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's accrued expenses?
- Syndax Pharmaceuticals (SNDX) reported accrued expenses of $74.84M in Q1 2026.
- How has Syndax Pharmaceuticals's accrued expenses changed year-over-year?
- Syndax Pharmaceuticals's accrued expenses increased by 33.7% year-over-year, from $55.98M to $74.84M.
- What is the long-term trend for Syndax Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's accrued expenses has grown at a 33.5% compound annual growth rate (CAGR), from $24.28M to $103.06M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.